Rubraca (rucaparib) — CareFirst (Caremark)

Initial criteria

• Member has germline or somatic BRCA-mutated recurrent disease and is in complete or partial response to platinum-based chemotherapy
• OR member has advanced (stage II–IV) disease and is in complete or partial response to primary therapy AND either (primary therapy included bevacizumab and member has germline or somatic BRCA‑mutated disease) OR (primary therapy did not include bevacizumab)

Reauthorization criteria

• No evidence of unacceptable toxicity or disease progression while on current regimen

Approval duration

12 months